Why in news?
A scientific review published on 28 October 2026 examines how macrophages adapt to their surroundings in health and disease. Macrophages are white blood cells involved in clearing unwanted material and coordinating immune responses. The review in Cellular & Molecular Immunology brings together research on their origins, local environment and changing functions. Earlier experimental studies have linked some macrophage populations showing stress-related cellular ageing with lung-cancer development. This raises a biological question: how can cells that normally protect tissue sometimes help create conditions favourable to a tumour? The new publication is a review of existing evidence, rather than a new human treatment trial. Understanding the individual studies is therefore essential to judging what the findings mean.
Protective cells do more than remove germs
The United States National Cancer Institute describes macrophages as cells that remove microorganisms and dead cells while stimulating other immune cells. Engulfing material is called phagocytosis. It helps clear debris that would otherwise remain within tissue. Communication is also part of the job: an immune response requires cells to respond together rather than act as isolated particles. The same broad cell family can therefore contribute both to defence and to the maintenance of functioning tissue.
Macrophages also have different developmental origins and locations. Some populations become established during embryonic development and maintain themselves within tissues. Others arise from circulating monocytes, another kind of white blood cell, particularly during inflammation. In the lungs, alveolar macrophages occupy the air spaces where gas exchange occurs. Their position exposes them to a distinctive local environment. A cell's developmental history and the signals around it help shape what it does.
A tumour includes its surroundings
A tumour is not just a collection of abnormal cancer cells. Its microenvironment includes nearby immune cells, other normal cells, blood vessels and signalling molecules. The National Cancer Institute emphasises that the relationship works in both directions. A tumour can alter its surroundings, and those surroundings can influence its behaviour. This makes immune-cell function part of the cancer problem. Counting macrophages alone cannot reveal whether they are protecting the tissue or supporting harmful processes.
Researchers sometimes describe macrophages using the labels M1 and M2, associated broadly with inflammatory and reparative responses. These are useful experimental reference points, but real tissue populations occupy a wider range of states. Consensus guidelines published in Immunity in 2014 emphasised the need to move beyond an overly simple two-type classification. A fixed division into two types can miss important differences within the same organ. It is more informative to ask which cells are present, what signals they receive and how their behaviour affects neighbouring cells.
What senescence means in this discussion
Cellular senescence is a response to stress associated with a lasting halt in cell division and other changes in cell behaviour. It can help prevent damaged cells from multiplying. However, senescence-associated cells can remain biologically active and release signals that influence surrounding tissue. The age of a person and the state of an individual cell are different things. A senescence-associated macrophage population is therefore not simply another name for every macrophage in an older lung.
The original lung-cancer experiments provide a specific clue
A 2023 study in Cancer Cell investigated this question in a mouse model of lung-tumour development. The researchers identified a subset of alveolar macrophages with several senescence-associated features. These cells accumulated early in tumour development and suppressed responses by cytotoxic T cells, immune cells capable of killing abnormal cells. Removing the identified population reduced early tumour development and progression in the mice. That intervention supplied evidence that the cells were contributing to the process within the model.
The investigators also identified macrophages with related characteristics in human early lung-cancer samples. This observation strengthens the reason to investigate the phenomenon in people, but it is a different kind of evidence. Finding a population in human tissue does not show that removing it improves survival or prevents cancer. The experimental result and the human observation should be read together, while preserving that distinction. The study concerns a particular subset and disease context, rather than all lung macrophages.
Later research examines another signalling connection
A February 2026 study in Journal of Translational Medicine examined lung adenocarcinoma, a major form of lung cancer. It combined several forms of molecular analysis with clinical specimens, cell experiments and animal tumour models. The researchers investigated macrophages associated with CXCL16, a signalling protein, and senescence-related features. Their findings implicated signalling through transforming growth factor beta in tumour-promoting effects within the experimental systems. This supplies a further research direction, rather than a universal explanation for lung cancer.
The distinction between molecular evidence and clinical benefit remains important. A protein associated with a cell state may help researchers identify a population or investigate its function. It does not automatically become a reliable diagnostic test. Similarly, an experimental intervention can help establish a mechanism without being ready for routine care. This study did not establish a macrophage-directed treatment that improves patient outcomes in a randomised clinical trial.
Healthy ageing and marker tests need separate interpretation
A different study, published in Nature Communications on 7 October 2026, examined lung macrophages during healthy old age. It included observations in mice, non-human primates and people, with experiments in mice investigating the influence of the lung environment. The results indicated that local surroundings could change resident-cell states and recruitment of other macrophages. This was a study of ageing lung biology, rather than a trial of cancer prevention. Its cell populations should not automatically be equated with every tumour-associated subset described elsewhere.
Even identifying senescence requires care. An original 2017 study showed that macrophages can display commonly used senescence markers during a reversible response to immune signals. A marker is a measurable characteristic used to recognise a cell state. Its presence alone may have more than one explanation. Researchers therefore need several lines of evidence, including cell behaviour and context. This qualification helps prevent a laboratory label from becoming an overconfident claim about a patient's disease or biological age.
Conclusion
The research points to a more precise understanding of immune ageing: particular cell states can change the conditions around a tumour. It also shows why protective and harmful functions cannot be assigned to every macrophage in the same way. Original experiments support further investigation of selected populations. Clinical usefulness will depend on accurately identifying those cells and demonstrating that an intervention is beneficial and safe in people.